Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases
NCT ID: NCT03841045
Last Updated: 2019-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2016-09-14
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immune Regulation in Ulcerative Colitis or Crohn s Disease
NCT00001184
Interactions Between Immune Cells of Intestinal Mucosa or Peripheral Blood With the Extracellular Matrix in Inflammatory Bowel Disease (IBD)
NCT00915044
Immunological Characteristics of Patients With PID and IBD
NCT03148028
Study of Inflammatory Markers (VNN1) in Crohn Disease and Ulcerative Colitis.
NCT02304666
Exacerbating Factors in Inflammatory Bowel Disease
NCT01405105
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The goals of this project are to examine a potential link between bilirubin metabolism and IBD, by comparing fecal extracts from healthy humans and IBD patients, and to investigate the underlying mechanism explaining these differences.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ulcerative colitis patient
people that have UC diagnosis can participate in the study. the disease can be at any level and the patients can handle any medications.
No interventions assigned to this group
CD patient
people that have CD diagnosis can participate in the study. the disease can be at any label and the patients can handle any medications.
No interventions assigned to this group
Health people
control group. no IBD patients can be included. patients with other diseases can be included.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CD
* healthy Volunteers
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Soroka University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ARIK SEGAL MD
principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ARIK SEGAL, MD
Role: PRINCIPAL_INVESTIGATOR
SOROKA MC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
soroka MC
Beersheba, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0148-15 SOR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.